Patents by Inventor Gary Mathias

Gary Mathias has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11925688
    Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: March 12, 2024
    Assignee: Thetis Pharmaceuticals LLC
    Inventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jr., Jessica J. Dworak
  • Publication number: 20230133085
    Abstract: The present invention relates to compositions comprising resolvins and their use in methods of treating cancer.
    Type: Application
    Filed: October 26, 2022
    Publication date: May 4, 2023
    Applicants: Thetis Pharmaceuticals LLC, Beth Israel Deaconess Medical Center
    Inventors: Gary Mathias, Dipak Panigrahy, John Parkinson, Aaron Mathias, Frank C. Sciavolino
  • Publication number: 20220031851
    Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.
    Type: Application
    Filed: October 1, 2021
    Publication date: February 3, 2022
    Inventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, JR., Jessica J. Dworak
  • Patent number: 11191840
    Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both. Provided are pharmaceutical compositions adapted to deliver the compounds the lower gastrointestinal tract and methods of using same as monotherapy in the treatment of inflammatory diseases or disorders of the lower gastrointestinal tract, and in combination therapy with 5-aminosalicylate.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: December 7, 2021
    Assignee: Thetis Pharmaceuticals LLC
    Inventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jr., Jessica J. Dworak
  • Patent number: 11135298
    Abstract: The present invention relates to compounds of Formulas I-IV and compositions comprising same, including pharmaceutical compositions. The compounds of Formulas I-IV represent new salt forms of specialized pro-resolving mediators (“SPMs”) which include lipoxins, resolvins, protectins, and their aspirin-triggered counterparts. The SPM salts described here contain at least one or two SPM molecules ionically bound to at least one basic function that is provided by a scaffold as described in Formulas I-IV. Also provided are methods for pharmaceutical and non-pharmaceutical uses of such compounds and compositions describing same.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: October 5, 2021
    Assignee: Thetis Pharmaceuticals LLC
    Inventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jr., Jessica J. Dworak
  • Publication number: 20210138072
    Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both. Provided are pharmaceutical compositions adapted to deliver the compounds the lower gastrointestinal tract and methods of using same as monotherapy in the treatment of inflammatory diseases or disorders of the lower gastrointestinal tract, and in combination therapy with 5-aminosalicylate.
    Type: Application
    Filed: November 28, 2018
    Publication date: May 13, 2021
    Inventors: Frank C Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jessica J. Dworak
  • Publication number: 20200179521
    Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.
    Type: Application
    Filed: August 8, 2019
    Publication date: June 11, 2020
    Inventors: Frank C Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, JR., Jessica J. Dworak
  • Patent number: 10420843
    Abstract: The present invention relates to compounds of Formula IV, compositions comprising same, and their use in therapy wherein A and B are each independently a specialized pro-resolving mediator (“SPM”) molecule selected from an E series resolvin, a D series resolvin, and their aspirin-triggered counterparts, and M, R1, R2, X1and X2 are as defined herein.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: September 24, 2019
    Assignee: Thetis Pharmaceuticals LLC
    Inventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jr., Jessica J. Dworak
  • Patent number: 10130719
    Abstract: The present invention relates to compounds which are salts of specialized pro-resolving mediators (referred to herein as “SPMs”) which include lipoxins, resolvins, protectins, and their aspirin-triggered counterparts. The SPM salts described here contain at least one or two SPM molecules ionically bound to at least one basic function that is provided by a scaffold moiety as described herein, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: November 20, 2018
    Assignee: Thetis Pharmaceuticals LLC
    Inventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jr., Jessica J. Dworak
  • Publication number: 20180200375
    Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.
    Type: Application
    Filed: June 2, 2017
    Publication date: July 19, 2018
    Applicant: Thetis Pharmaceuticals LLC
    Inventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jr., Jessica J. Dworak
  • Patent number: 9999626
    Abstract: The present invention provides compounds of Formula I and related compositions and methods.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: June 19, 2018
    Assignee: Thetis Pharmaceuticals LLC
    Inventors: Frank C. Sciavolino, Gary Mathias
  • Publication number: 20180110751
    Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.
    Type: Application
    Filed: November 28, 2017
    Publication date: April 26, 2018
    Inventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, JR., Jessica J. Dworak
  • Publication number: 20170119841
    Abstract: The present invention provides compounds of Formula I and Formula II and related compositions and methods.
    Type: Application
    Filed: November 3, 2016
    Publication date: May 4, 2017
    Inventors: Gary Mathias, Frank C. Sciavolino
  • Publication number: 20170096449
    Abstract: The present invention relates to compounds of Formula I, compositions containing same, and methods of use.
    Type: Application
    Filed: October 25, 2016
    Publication date: April 6, 2017
    Inventors: Gary Mathias, Banavara L. Mylari, Frank C. Sciavolino
  • Patent number: 9505709
    Abstract: The present invention relates to compounds of Formula I, compositions containing same, and methods of use.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: November 29, 2016
    Inventors: Gary Mathias, Banavara L. Mylari, Frank C. Sciavolino
  • Publication number: 20160199385
    Abstract: The present invention provides compounds of Formula I and related compositions and methods.
    Type: Application
    Filed: June 12, 2015
    Publication date: July 14, 2016
    Inventors: Frank C. SCIAVOLINO, Gary MATHIAS
  • Publication number: 20160107985
    Abstract: The present invention relates to compounds of Formula I, compositions containing same, and methods of use.
    Type: Application
    Filed: May 4, 2015
    Publication date: April 21, 2016
    Inventors: Gary Mathias, Banavara L. Mylari, Frank C. Sciavolino
  • Patent number: 9242008
    Abstract: The present invention relates to compound of Formula III comprising an amino acid component, a divalent metal component, and a counter-ion component, compositions containing same, and methods of use.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: January 26, 2016
    Assignee: Thetis Pharmaceuticals LLC
    Inventors: Frank C. Sciavolino, Gary Mathias
  • Publication number: 20150366980
    Abstract: The present invention relates to compound of Formula III comprising an amino acid component, a divalent metal component, and a counter-ion component, compositions containing same, and methods of use.
    Type: Application
    Filed: October 1, 2014
    Publication date: December 24, 2015
    Inventors: Frank C. Sciavolino, Gary Mathias
  • Publication number: 20140148464
    Abstract: Provided herein are compositions for the treatment of dry eye, comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a fatty acid salt, and methods of use thereof.
    Type: Application
    Filed: November 27, 2013
    Publication date: May 29, 2014
    Applicant: Thetis Pharmaceuticals LLC
    Inventors: Banavara L. Mylari, Frank C. Sciavolino, Gary Mathias